Taurodeoxycholate sodium
Based on 7 publication(s) in Google Scholar
Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) exhibits anti-inflammatory and neuroprotective effects.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.91%
- No. CAS: 1180-95-6
- Fòrmula: C26H44NNaO6S
- Peso molecular:521.69
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-N0593
Deoxycholic acidBile Acid Receptor Activator -
HY-N0169
Hyodeoxycholic acidGPBAR1 Agonist -
HY-B1788
Taurocholic acidImmunoregulation Agent -
HY-B0172
Lithocholic acidAutophagy Inducer -
HY-N1423
Glycocholic acidBile Acid Derivative -
HY-19696A
Tauroursodeoxycholate sodiumEndoplasmic Reticulum Stress Inhibitor -
HY-125731
Glycodeoxycholic acidEndogenous Metabolite -
HY-N0324
Cholic acidEndogenous Metabolite -
HY-N1424
Glycoursodeoxycholic acidEndogenous Metabolite -
HY-N2027
Taurochenodeoxycholic acidEndogenous Metabolite -
HY-N2334
Glycochenodeoxycholic acidEndogenous Metabolite -
HY-N1429
Taurochenodeoxycholic acid sodiumAnti-inflammatory Drug
Publications Citing Use of MedChemExpress (MCE) Taurodeoxycholate sodium
More- Cell Host Microbe. 2025 Aug 19:S1931-3128(25)00291-4. [Abstract]
- Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]
- Research (Wash D C). 2022 Nov 2:2022:9784081. [Abstract]
- J Transl Med. 2024 Dec 20;22(1):1124. [Abstract]
- Biomedicines. 2025 Apr 4;13(4):874. [Abstract]
- Metabolomics. 2026 Jun 18;22(4):103.
- SSRN. 2022 Jan 26.
Customer Validation & Images
-
RT-PCR
-
RT-PCR
Ver todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
Descripciòn
In Vitro
Taurodeoxycholate sodium salt (Taurodeoxycholic acid form) shows agonist activity at human TGR5 expressed in CHO cells by luciferase assay, with an EC50 of 0.79 μM[4].
Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 16 h) shows agonist activity at wild type and Y89A mutant human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level, with EC50s of 0.68 and 8.9 μM, respectively[5].
Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 50 μM, 100 μM; 4 h) increases oligonucleosomal DNA cleavage and apoptotic nuclei in primary human hepatocytes[6].
Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 400 μM, 18-24 h) increases DNA fragmentation and PARP cleavage in human liver-derived cell line Huh7 cells, thus induces apoptosis[8].
Taurodeoxycholate (0.05-1.00 mM; 1-6 days) sodium salt stimulates intestinal epithelial cell proliferation[8].
Taurodeoxycholate (0.05-1.00 mM; 24 h) sodium salt induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells[8].
Taurodeoxycholate (25-400 ng/mL, with a four-fold dilution, 3 h) sodium salt inhibits the activation of NF-κB in lipopolysaccharide-activated bone marrow-derived macrophages (BMDMs) by activating the cAMP-PKA axis[9].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:IEC-6 and caco-2 cells
-
Concentration:0, 0.05, 0.50, and 1.00 mM
-
Incubation Time:1, 2, 4 and 6 days
-
Result:Significantly stimulated intestinal epithelial cell proliferation in a dose-dependent manner.
-
Cell Line:IEC-6 and caco-2 cells
-
Concentration:0, 0.05, 0.50, and 1.00 mM
-
Incubation Time:24 h
-
Result:Significantly increased cells in S phase and decreased cells in G1-phase.
-
Cell Line:IEC-6 and caco-2 cells
-
Concentration:0.5 mM
-
Incubation Time:1 and 6 days
-
Result:Significantly increased c-myc protein expression.
In Vivo
Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 50 mg/kg; i.p.; once daliy for 34 d) prevents neuropathology and associated behavioral deficits in the 3-nitropropionic acid rat model of Huntington's disease (HD) [10].
Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 500 mg/kg; s.c.; once every 3 d for 7 weeks) leads to a significant reduction in striatal neuropathology of the R6/2 transgenic HD mouse[11].
Taurodeoxycholate (0.5 mg/kg; i.v., once) sodium salt confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[12].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A mouse colitis model (fed with 3% (w/v) DSS in drinking water for the first seven days and then switched to normal drinking water for an additional two days)[9]
-
Dosage:1.25, 2.5, and 5 mg/kg
-
Administration:Oral gavage (p.o.), from day 3 to day 8, once a day
-
Result:Prevented loss of body weight, shortening of the colon, production of pro-inflammatory cytokines, infiltration of pro-inflammatory cells, and mucosal ulceration in the colon.
-
Animal Model:Huntington's disease model in mouse[10]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection; once daliy for 34 d, injected 3-NP at 6 hr after Taurodeoxycholic acid treatment
-
Result:Reduced striatal atrophy, decreased striatal apoptosis, as well as fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions.
Significantly improved locomotor and sensorimotor deficits.
-
Animal Model:C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis[12]
-
Dosage:0.5 mg/kg
-
Administration:Intravenous injection, 30 min or 24 h after LPS injection
-
Result:Improved the survival rate of mice with sepsis.
Decreased liver and kidney damage in septic mice.
Ameliorated systemic inflammation and normalized blood pressure in septic mice.
Chemical Information
-
No. CAS 1180-95-6
-
Appearance Solid
-
Peso molecular 521.69
-
Fòrmula C26H44NNaO6S
-
Color White to off-white
-
SMILES
C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell Host Microbe
2025 Aug 19:S1931-3128(25)00291-4. PMID: 40848719 -
Adv Sci (Weinh)
Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]2025 Mar;12(12):e2411719. PMID: 39899681
Taurodeoxycholate sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]
The mRNA levels of ALDOB in Huh7 cells treated with various bile acids. All groups were compared with control group vehicle. n=3. Cells were treated with cholesterol (10 μg/ml), YM-53601 (5 μM) or various indicated bile acids (100 μM) for 24 h. CA, Cholic acid; TCA, Taurocholic acid; GCA, Glycocholic acid; TCDCA, Taurochenodeoxycholic acid; GCDCA, Glycochenodeoxycholic acid; LCA, Lithocholic acid; TLCA, Taurolithocholic acid; GLCA, Glycolithocholic acid; DCA, Deoxycholic acid; TDCA, Taurodeoxycholic acid; GDCA, Glycodeoxycholic acid; UDCA, Ursodeoxycholic acid; TUDCA, Tauroursodeoxycholic acid; GUDCA, Glycoursodeoxycholic acid.
Taurodeoxycholate sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]
The mRNA levels of ALDOB in HCCLM3 cells treated with various bile acids. All groups were compared with control group vehicle. n=3. Cells were treated with cholesterol (10 μg/ml), YM-53601 (5 μM) or various indicated bile acids (100 μM) for 24 h. CA, Cholic acid; TCA, Taurocholic acid; GCA, Glycocholic acid; TCDCA, Taurochenodeoxycholic acid; GCDCA, Glycochenodeoxycholic acid; LCA, Lithocholic acid; TLCA, Taurolithocholic acid; GLCA, Glycolithocholic acid; DCA, Deoxycholic acid; TDCA, Taurodeoxycholic acid; GDCA, Glycodeoxycholic acid; UDCA, Ursodeoxycholic acid; TUDCA, Tauroursodeoxycholic acid; GUDCA, Glycoursodeoxycholic acid.
-
Research (Wash D C)
Activation of Pancreatic Acinar FXR Protects against Pancreatitis via Osgin1-Mediated Restoration of Efficient Autophagy. [Abstract]2022 Nov 2:2022:9784081. PMID: 36405253 -
J Transl Med
Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]2024 Dec 20;22(1):1124. PMID: 39707318 -
Biomedicines
2025 Apr 4;13(4):874. PMID: 40299495 -
-
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (191.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (287 KB)
-
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Villavicencio-Queijeiro A, et al. The fully-active and structurally-stable form of the mitochondrial ATP synthase of Polytomella sp. is dimeric. J Bioenerg Biomembr. 2009 Feb;41(1):1-13. [Content Brief]
[2]. Kispal G, et al. Isolation and characterization of 3-hydroxyacyl coenzyme A dehydrogenase-binding protein from pig heart inner mitochondrial membrane. J Biol Chem. 1986 Oct 25;261(30):14209-13. [Content Brief]
[3]. Choi HJ, et al. Evaluation of acute and subacute toxicity of sodium taurodeoxycholate in rats. Drug Chem Toxicol. 2021 May;44(3):268-276. [Content Brief]
[4]. Sato H, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41. [Content Brief]
[5]. Gertzen CG, et al. Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists. Eur J Med Chem. 2015 Nov 2;104:57-72. [Content Brief]
[6]. Benz C, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000 Mar;30(3):203-9. [Content Brief]
[7]. Xie Q, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology. 2002 Sep;36(3):592-601. [Content Brief]
[8]. Yamaguchi J, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135(2):215-21. [Content Brief]
[9]. Zou Y, et al. Taurodeoxycholate ameliorates DSS-induced colitis in mice. Int Immunopharmacol. 2023 Sep;122:110628. [Content Brief]
[10]. Keene CD, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60. [Content Brief]
[11]. Keene CD, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. [Content Brief]
[12]. Chang S, et al. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9168 mL | 9.5842 mL | 19.1685 mL | 47.9212 mL |
| 5 mM | 0.3834 mL | 1.9168 mL | 3.8337 mL | 9.5842 mL | |
| 10 mM | 0.1917 mL | 0.9584 mL | 1.9168 mL | 4.7921 mL | |
| 15 mM | 0.1278 mL | 0.6389 mL | 1.2779 mL | 3.1947 mL | |
| 20 mM | 0.0958 mL | 0.4792 mL | 0.9584 mL | 2.3961 mL | |
| 25 mM | 0.0767 mL | 0.3834 mL | 0.7667 mL | 1.9168 mL | |
| 30 mM | 0.0639 mL | 0.3195 mL | 0.6389 mL | 1.5974 mL | |
| 40 mM | 0.0479 mL | 0.2396 mL | 0.4792 mL | 1.1980 mL | |
| 50 mM | 0.0383 mL | 0.1917 mL | 0.3834 mL | 0.9584 mL | |
| 60 mM | 0.0319 mL | 0.1597 mL | 0.3195 mL | 0.7987 mL | |
| 80 mM | 0.0240 mL | 0.1198 mL | 0.2396 mL | 0.5990 mL | |
| 100 mM | 0.0192 mL | 0.0958 mL | 0.1917 mL | 0.4792 mL |
Taurodeoxycholate sodium Related Classifications
HY-128853 Related Classifications
Powered by Bioz
Keywords
- Taurodeoxycholate
- 1180-95-6
- Endogenous Metabolite
- G protein-coupled Bile Acid Receptor 1
- PARP
- Apoptosis
- NF-κB
- PKA
- G-protein coupled receptor 19
- GPCR19
- TGR5
- GPBAR1
- poly ADP ribose polymerase
- Nuclear factor-κB
- Nuclear factor-kappaB
- Protein kinase A
- BMDMs
- CHO
- Huh7
- IEC-6
- Huntington's disease
- Colitis
- Anti-inflammatory.
- Inhibitor
- inhibitor
- inhibit